SCHEMBL5136045

SCHEMBL5136045

CCCCn1c(CN(Cc2ccc(SC)cc2)Cc2cccc3ccccc23)cnc1-c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.37
PPARA Q07869 2/20 0.37
TSHR P16473 2/20 0.36
C5AR1 P21730 1/20 0.35
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
HSD11B1 P28845 2/20 0.34
CYP2C19 P33261 1/20 0.34
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
LMNA P02545 2/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPBWR1 P48145 1/20 0.33
NR1I2 O75469 1/20 0.32
ADRA2A P08913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137361 0.92 PPARG (0.36) PPARGPPARATSHRC5AR1FNTA
SCHEMBL5072389 0.92 TSHR (0.41) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5137298 0.91 PPARG (0.39) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5072207 0.91 PPARG (0.39) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5135150 0.90 HSD11B1 (0.40) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5137554 0.89 MAPT (0.38) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5135214 0.89 TSHR (0.43) TSHRC5AR1HSD11B1ALDH1A1HPGD
SCHEMBL5135533 0.88 PPARG (0.44) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5136060 0.88 CASR (0.40) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5134565 0.88 PPARG (0.42) PPARGPPARATSHRC5AR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed